With ommision of FS analysis, operation cost, operative time and anesthetic side effects are projected to decrease.īreast cancer is one of the most common types of cancer worldwide with more than 2 million newly diagnosed cases in 2020.

We conclude that the implementation of SLNB with PS analysis alone in patients who satisfy the ACOSOG Z0011 criteria, with a re-operation rate of 0%, does not have outcomes that would be altered by the standard of care additional FS analysis. None of the patients were subjected to a second surgical procedure. The remaining 212 (88.7%) patients had no nodal metastasis. Out of 239 patients, 21 (8.8%) and 6 (2.5%) had metastatic disease in 1 and 2 nodes, respectively. A total of 975 SLNs were removed from these 239 patients, with an average of 4.15 nodes per patient. Resultīetween April 2016 and April 2021, 239 patients who had undergone SLNB in accordance with ACOSOG Z0011 criteria with PS alone was enrolled.

The re-operation rate was determined by the number of positive SLNs where 3 more nodal metastases were subjected to a second surgical procedure. The clinical nodal status was assessed from physical examination. The patients were diagnosed with primary invasive breast cancer with clinically negative nodes. We retrospectively reviewed 239 SLNB cases without FS at King Chulalongkorn Memorial Hospital from April 2016 to April 2021. This pilot study conducted in Thailand determines the re-operation rate for SLNB without FS. In 2021, there is an increased global trend for sending sentinel lymph node biopsy (SLNB) specimens for permanent section (PS) without intraoperative frozen sections (FS).

Lumpectomy and sentinel node biopsy